Stockscreener 앱 받기
4.585
2.93%
0.145
전일 마감가:
$4.44
열려 있는:
$4.49
하루 거래량:
1.21M
Relative Volume:
0.60
시가총액:
$1.41B
수익:
$248.37M
순이익/손실:
$11.74M
주가수익비율:
91.70
EPS:
0.05
순현금흐름:
$18.24M
1주 성능:
-1.51%
1개월 성능:
-12.45%
6개월 성능:
-31.18%
1년 성능:
+11.19%
1일 변동 폭
$4.48
$4.69
1주일 범위
$4.40
$4.69
52주 변동 폭
$4.06
$7.63
맨카인드 Stock (MNKD) Company Profile
명칭
Mannkind Corp
전화
818-661-5000
주소
1 CASPER STREET, DANBURY, CA
MNKD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
4.585 | 1.41B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.02 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.46 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.84 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.78 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.28 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
맨카인드 Stock (MNKD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-10 | 개시 | Wedbush | Outperform |
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-12-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-10-10 | 개시 | Wedbush | Outperform |
| 2021-05-14 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 개시 | Oppenheimer | Outperform |
| 2019-10-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 개시 | BTIG Research | Buy |
| 2019-03-04 | 개시 | SVB Leerink | Outperform |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2018-02-28 | 다운그레이드 | Maxim Group | Hold → Sell |
| 2017-11-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-10 | 개시 | H.C. Wainwright | Buy |
| 2017-10-06 | 재확인 | Maxim Group | Buy |
| 2017-08-11 | 개시 | Maxim Group | Buy |
| 2016-05-10 | 재확인 | Piper Jaffray | Underweight |
| 2016-05-10 | 재확인 | RBC Capital Mkts | Underperform |
| 2016-01-06 | 재확인 | Piper Jaffray | Underweight |
| 2016-01-06 | 재확인 | RBC Capital Mkts | Underperform |
| 2015-11-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | 다운그레이드 | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-05-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 재확인 | MLV & Co | Hold |
| 2015-04-16 | 재확인 | RBC Capital Mkts | Outperform |
모두보기
맨카인드 주식(MNKD)의 최신 뉴스
Is MannKind Corporation (MNKD) the Best Quality Penny Stock to Buy According to Hedge Funds? (READY TO EDIT2) - Insider Monkey
Is MannKind Corp. (NASDAQ:MNKD) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
MannKind Co. (NASDAQ:MNKD) Shares Sold by Prudential Financial Inc. - MarketBeat
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Mizuho sets MannKind stock Outperform with $12 target - Investing.com
Mizuho sets MannKind stock Outperform with $12 target By Investing.com - Investing.com India
Diabetes Meets Racing: MannKind's Game-Changing Partnership With Type 1 Diabetic IndyCar Star - Stock Titan
MannKind To Support Conor Daly - speed sport
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options - Yahoo Finance
Cantor maintains Overweight rating on MannKind stock at $9 target - Investing.com
Why It's Worth Keeping An Eye On MannKind - RTTNews
Inhalable Biologics Industry Report 2025: World Market to Nearly Triple in Size by 2030, Reaching $10.06 Billion at a CAGR of 17.6% - Yahoo Finance
MannKind at Barclays Healthcare Conference: Strategic Growth and Innovation - Investing.com India
MAC Lung Disease Market Statistics Expected to Experience Major - openPR
MannKind Corporation Showcases Positive Outcomes of Inhaled Insulin at ATTD 2025 with Anticipated sNDA Filing for Pediatric Use in 2025 - Nasdaq
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22 - Yahoo Finance
AllPennyStocks.com News: Companies Looking Towards Future Revenue with New Diabetes Therapies - ACCESS Newswire
Commit To Purchase MannKind At $3, Earn 13.3% Using Options - Nasdaq
Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma - Barchart
Non- Tuberculous Mycobacterial Infections Market on Track - openPR
MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’ - MSN
MannKind Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
MannKind Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Decoding MannKind Corp (MNKD): A Strategic SWOT Insight - GuruFocus.com
MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question - Seeking Alpha
MannKind Corporation (NASDAQ:MNKD) Q4 2024 Earnings Call Transcript - Insider Monkey
MannKind: Q4 Earnings Snapshot - mySA
MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Re - GuruFocus.com
MannKind Corp Q4 Earnings: EPS Meets Estimates at $0.03, Revenue Surpasses Expectations at $77 Million - GuruFocus.com
MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Mannkind stock gains amid Q4 report, business update - MSN
MannKind Corp reports results for the quarter ended December 31Earnings Summary - TradingView
MannKind (MNKD) Q4 Earnings Meet Estimates - Yahoo Finance
Earnings call transcript: MannKind Q4 2024 beats EPS forecast, stock jumps - Investing.com
MannKind earnings beat by $0.05, revenue topped estimates - Investing.com
MannKind shares move 4% higher on strong revenue growth By Investing.com - Investing.com South Africa
MannKind shares move 4% higher on strong revenue growth - Investing.com
MANNKIND CORP SEC 10-K Report - TradingView
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
MannKind Corp (MNKD) Q4 2024 Earnings Report Preview: What To Expect - Yahoo Finance
Exploring Three High Growth Tech Stocks in the United States - Yahoo Finance
MannKind: Q2 Earnings Snapshot -August 07, 2024 at 08:09 am EDT - Marketscreener.com
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025 - Yahoo Finance
MannKind Sets Stage for 2024 Performance Review: CEO and CFO to Unveil Full Year Results - Stock Titan
MannKind (MNKD) Expected to Announce Earnings on Tuesday - MarketBeat
Wedbush Initiates Coverage on MannKind (NASDAQ:MNKD) - MarketBeat
MannKind To Present At Oppenheimer Healthcare Life Sciences Conference; Webcast At 11:20 AM ET - Nasdaq
An Analysis of Mannkind Corp (MNKD)’s Potential Price Growth - Knox Daily
맨카인드 (MNKD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
맨카인드 주식 (MNKD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Binder Steven B. | Director |
Nov 22 '24 |
Sale |
6.89 |
67,536 |
465,323 |
1,075,026 |
1.75%
2.22%
자본화:
|
볼륨(24시간):